BRIEF-Adaptimmune Therapeutics says FDA grants orphan drug designation to its t-cell therapy
* U.S. Food and drug administration grants orphan drug designation to adaptimmune's t-cell therapy targeting ny-eso for treatment of soft tissue sarcoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
No comments:
Post a Comment